Research indicates that the new blood test for Alzheimer’s disease can accurately discover people with premature symptoms.
Mayo Clinic experts in the United States provided additional evidence that blood tests can accurately diagnose dementia by examining proteins in blood plasma.
Proteins-Amyloid Beta 42/40 and P-TAU217- Ptrlalaidoid accumulation, which is characterized by Alzheimer’s disease.
The researchers found that the blood test was very accurate, with 95 % sensitivity, which means it was 95 % accurate in capturing people with memory problems, with very few cases.
It was also 82 % for privacy, which means it was very accurate in excluding people without dementia.
The study was conducted on more than 500 people in an outpatient memory clinic, which means that they are data in the real world.
The blood test was approved by the United States Food and Drug Administration.
Dr. Greg Day, who led the study in Al -Zheimer’s Journal and DifferenceHe said the test was as good as the invasive tests used.
“Our study has found that the blood test confirmed the diagnosis of Alzheimer’s disease with 95 % allergies and 82 % privacy,” he said.
“When it is implemented in the clinical preparation for external patients, this is similar to the accuracy of the vital indicators of the masculine fluids of the disease and is more appropriate and effective.”
In general, researchers found that P-Tau217 levels were higher in patients with Alzheimer’s disease against those who have no disease.
Dai said that the following steps in the research are to evaluate blood -based tests in more varied groups for patients and people with early Alzheimer’s disease who have not shown any cognitive symptoms.
The results “indicate that this test is very accurate” and can be used alongside tests and other notes from a coach’s health specialist.
“This study shows how blood tests perform a diagnosis of Alzheimer’s disease faster, easier and easier than ever in a real environment,” he added.
“Although focus on Alzheimer’s disease, the test has been evaluated in people who have other types of dementia as well, which indicates that it may help distinguish between the causes of cognitive decline, although more research is needed in various groups of individuals and in societal settings.
“Diagnostic options in the UK are often slow and expensive and can be gas, which means that thousands miss the benefits that one can achieve.
“It is great to see blood tests like this approved for clinical use in the United States. We hope to see the same thing in NHS, which is why we are part of the vital brand challenge.”
The vital signs challenge is a research program with millions of pounds supported by Al -Zheimer’s Association, Al -Zheimer Research in the United Kingdom and the National Institute in favor of health And care research. Its goal is to bring blood tests to diagnose dementia to the national health service by 2029.
“Blood tests will be very important to accelerate the diagnosis and give more people access to care, support and treatments they need faster than ever,” said Okley.
))
“We urgently need to improve how to diagnose dementia and it is wonderful to see international research working towards this goal,” said Dr. Julia Dodley, head of research in Alzheimer’s disease in the UK.
“Blood tests in this study are viewed by P-Tau217 and Beta 42/40, and tests that provided high accuracy showed Alzheimer’s disease.
“This study adds to the increasing evidence that blood tests can detect diseases that cause dementia in people with early memory problems and thinking.
“There is an important point that must be taken into account is that people who participate in the research do not always reflect the full diversity of those affected by dementia, who may have additional conditions or other properties.
This is why work is needed to understand whether these blood tests are working in a real place.
“In the United Kingdom, studies such as biopal brand challenges help build this evidence. The study tests blood tests, including P-Tau217, in thousands of sites throughout the UK.
“This work will be a decisive part of making the diagnosis easier and faster, which will bring us closer to treatment.”
